Buyer Name: NHS England
Buyer Address: Wellington House, 133-135 Waterloo Rd, London, UKJ1, SE1 8UG, United Kingdom
Contact Name: Jessica Gaucher-Thompson
Contact Email: jessica.gaucher-thompson@nhs.net
Tumour Infiltrating Lymphocyte(TIL) Therapy Hubs for Melanoma(Adults)
Buyer Contact Info
Status
complete
complete
Procedure
open
open
Value
11876000.0 GBP
11876000.0 GBP
Published
16 Jan 2026, 12:42
16 Jan 2026, 12:42
Deadline
n/a
n/a
Contract Start
n/a
n/a
Contract End
n/a
n/a
Category
services
services
CPV
85100000 - Health services
85100000 - Health services
Region
n/a
n/a
Awarded To
University College London Hospitals NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust, Barts Health NHS Trust, The Royal Marsden NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust, Oxford University Hospitals NHS FT, University Hospitals Southampton, University Hospitals Bristol and Weston NHS Foundation Trust, UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST, The Newcastle upon Tyne Hospitals NHS Foundation Trust, The Christie NHS Foundation Trust, THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST
University College London Hospitals NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust, Barts Health NHS Trust, The Royal Marsden NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust, Oxford University Hospitals NHS FT, University Hospitals Southampton, University Hospitals Bristol and Weston NHS Foundation Trust, UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST, The Newcastle upon Tyne Hospitals NHS Foundation Trust, The Christie NHS Foundation Trust, THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST
Official Source
Open Find a Tender
Open Find a Tender
Description
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults). <br/><br/>Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy<br/>Unit (ITU).<br/><br/>Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752<br/><br/>The treatment is complex to administer, requiring surgical expertise for tumour<br/>resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.<br/><br/>The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:<br/>Lot 1: London<br/>Lot 2: East of England<br/>Lot 3: South East<br/>Lot 4: South West<br/>Lot 5: Midlands<br/>Lot 6: North East and Yorkshire<br/>Lot 7: North West<br/><br/>This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.<br/><br/>As a result of this procurement exercise the commissioner intends to award 12 separate contracts across the 7 Lots.<br/><br/>The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).
Linked Documents
No linked documents found for this notice.
Opportunity Context
Lots
Lot Title: Lot 1 - London
Lot Description: NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy<br/>Unit (ITU).<br/><br/>Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752<br/><br/>The treatment is complex to administer, requiring surgical expertise for tumour<br/>resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.<br/><br/>The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:<br/>Lot 1: London<br/>Lot 2: East of England<br/>Lot 3: South East<br/>Lot 4: South West<br/>Lot 5: Midlands<br/>Lot 6: North East and Yorkshire<br/>Lot 7: North West<br/><br/>This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.<br/><br/>As a result of this procurement exercise, the Commissioner intends to award four separate contracts under Lot 1 - London. <br/><br/>The approximate lifetime value of each contract is £11,876,000, subject to the number of patients treated.<br/><br/>The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).
Lot 1 Status: cancelled
Lot 1 Has Options: Yes
Lot 1 Options: Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).
Lot 1 Award Criterion (quality): Quality & innovation
Lot 1 Award Criterion (quality): Value
Lot 1 Award Criterion (quality): Integration, Collaboration & Service Sustainability
Lot 1 Award Criterion (quality): Improving Access, Reducing Health Inequalities and Facilitating Choice
Lot 1 Award Criterion (quality): Social Value
Lot 1 Award Criterion (cost): Not Applicable
Lot Title: Lot 2 - East of England
Lot Description: NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy<br/>Unit (ITU).<br/><br/>Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752<br/><br/>The treatment is complex to administer, requiring surgical expertise for tumour<br/>resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.<br/><br/>The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:<br/>Lot 1: London<br/>Lot 2: East of England<br/>Lot 3: South East<br/>Lot 4: South West<br/>Lot 5: Midlands<br/>Lot 6: North East and Yorkshire<br/>Lot 7: North West<br/><br/>This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.<br/><br/>As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 2 - East of England.<br/><br/>The approximate lifetime value of the contract is £11,876,000, subject to the number of patients treated.<br/><br/>The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).
Lot 2 Status: cancelled
Lot 2 Has Options: Yes
Lot 2 Options: Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).
Lot 2 Award Criterion (quality): Quality & innovation
Lot 2 Award Criterion (quality): Value
Lot 2 Award Criterion (quality): Integration, Collaboration & Service Sustainability
Lot 2 Award Criterion (quality): Improving Access, Reducing Health Inequalities and Facilitating Choice
Lot 2 Award Criterion (quality): Social Value
Lot 2 Award Criterion (cost): Not Applicable
Lot Title: Lot 3: South East
Lot Description: NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy<br/>Unit (ITU).<br/><br/>Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752<br/><br/>The treatment is complex to administer, requiring surgical expertise for tumour<br/>resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.<br/><br/>The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:<br/>Lot 1: London<br/>Lot 2: East of England<br/>Lot 3: South East<br/>Lot 4: South West<br/>Lot 5: Midlands<br/>Lot 6: North East and Yorkshire<br/>Lot 7: North West<br/><br/>This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.<br/><br/>As a result of this procurement exercise, the Commissioner intends to award two separate contracts under Lot 3 - South East.<br/><br/>The approximate lifetime value of each contract is £11,876,000, subject to the number of patients treated.<br/><br/>The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).
Lot 3 Status: cancelled
Lot 3 Has Options: Yes
Lot 3 Options: Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).
Lot 3 Award Criterion (quality): Quality & innovation
Lot 3 Award Criterion (quality): Value
Lot 3 Award Criterion (quality): Integration, Collaboration & Service Sustainability
Lot 3 Award Criterion (quality): Improving Access, Reducing Health Inequalities and Facilitating Choice
Lot 3 Award Criterion (quality): Social Value
Lot 3 Award Criterion (cost): Not Applicable
Lot Title: Lot 4: South West
Lot Description: NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy<br/>Unit (ITU).<br/><br/>Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752<br/><br/>The treatment is complex to administer, requiring surgical expertise for tumour<br/>resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.<br/><br/>The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:<br/>Lot 1: London<br/>Lot 2: East of England<br/>Lot 3: South East<br/>Lot 4: South West<br/>Lot 5: Midlands<br/>Lot 6: North East and Yorkshire<br/>Lot 7: North West<br/><br/>This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.<br/><br/>As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 4 - South West.<br/><br/>The approximate lifetime value of the contract is £11,876,000, subject to the number of patients treated.<br/><br/>The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).
Lot 4 Status: cancelled
Lot 4 Has Options: Yes
Lot 4 Options: Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).
Lot 4 Award Criterion (quality): Quality & innovation
Lot 4 Award Criterion (quality): Value
Lot 4 Award Criterion (quality): Integration, Collaboration & Service Sustainability
Lot 4 Award Criterion (quality): Improving Access, Reducing Health Inequalities and Facilitating Choice
Lot 4 Award Criterion (quality): Social Value
Lot 4 Award Criterion (cost): Not Applicable
Lot Title: Lot 5: Midlands
Lot Description: NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy<br/>Unit (ITU).<br/><br/>Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752<br/><br/>The treatment is complex to administer, requiring surgical expertise for tumour<br/>resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.<br/><br/>The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:<br/>Lot 1: London<br/>Lot 2: East of England<br/>Lot 3: South East<br/>Lot 4: South West<br/>Lot 5: Midlands<br/>Lot 6: North East and Yorkshire<br/>Lot 7: North West<br/><br/>This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.<br/><br/>As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 5 - Midlands.<br/><br/>The approximate lifetime value of the contract is £11,876,000, subject to the number of patients treated.<br/><br/>The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).
Lot 5 Status: cancelled
Lot 5 Has Options: Yes
Lot 5 Options: Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).
Lot 5 Award Criterion (quality): Quality & innovation
Lot 5 Award Criterion (quality): Value
Lot 5 Award Criterion (quality): Integration, Collaboration & Service Sustainability
Lot 5 Award Criterion (quality): Improving Access, Reducing Health Inequalities and Facilitating Choice
Lot 5 Award Criterion (quality): Social Value
Lot 5 Award Criterion (cost): Not Applicable
Lot Title: Lot 6: North East & Yorkshire
Lot Description: NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy<br/>Unit (ITU).<br/><br/>Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752<br/><br/>The treatment is complex to administer, requiring surgical expertise for tumour<br/>resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.<br/><br/>The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:<br/>Lot 1: London<br/>Lot 2: East of England<br/>Lot 3: South East<br/>Lot 4: South West<br/>Lot 5: Midlands<br/>Lot 6: North East and Yorkshire<br/>Lot 7: North West<br/><br/>This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.<br/><br/>As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 6 - North East and Yorkshire.<br/><br/>The approximate lifetime value of the contract is £11,876,000, subject to the number of patients treated.<br/><br/>The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).
Lot 6 Status: cancelled
Lot 6 Has Options: Yes
Lot 6 Options: Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).
Lot 6 Award Criterion (quality): Quality & innovation
Lot 6 Award Criterion (quality): Value
Lot 6 Award Criterion (quality): Integration, Collaboration & Service Sustainability
Lot 6 Award Criterion (quality): Improving Access, Reducing Health Inequalities and Facilitating Choice
Lot 6 Award Criterion (quality): Social Value
Lot 6 Award Criterion (cost): Not Applicable
Lot Title: Lot 7: North West
Lot Description: NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy<br/>Unit (ITU).<br/><br/>Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752<br/><br/>The treatment is complex to administer, requiring surgical expertise for tumour<br/>resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.<br/><br/>The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:<br/>Lot 1: London<br/>Lot 2: East of England<br/>Lot 3: South East<br/>Lot 4: South West<br/>Lot 5: Midlands<br/>Lot 6: North East and Yorkshire<br/>Lot 7: North West<br/><br/>This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.<br/><br/>As a result of this procurement exercise, the Commissioner intends to award two separate contracts under Lot 7 - North West.<br/><br/>The approximate lifetime value of each contract is £11,876,000, subject to the number of patients treated.<br/><br/>The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).
Lot 7 Status: cancelled
Lot 7 Has Options: Yes
Lot 7 Options: Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).
Lot 7 Award Criterion (quality): Quality & innovation
Lot 7 Award Criterion (quality): Value
Lot 7 Award Criterion (quality): Integration, Collaboration & Service Sustainability
Lot 7 Award Criterion (quality): Improving Access, Reducing Health Inequalities and Facilitating Choice
Lot 7 Award Criterion (quality): Social Value
Lot 7 Award Criterion (cost): Not Applicable
Raw Notice JSON
Expand raw payload
{
"awards": [
{
"id": "003869-2026-1",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-171595",
"name": "University College London Hospitals NHS Foundation Trust"
}
]
},
{
"id": "003869-2026-2",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-135891",
"name": "Guy\u0027s and St Thomas\u0027 NHS Foundation Trust"
}
]
},
{
"id": "003869-2026-3",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-171596",
"name": "Barts Health NHS Trust"
}
]
},
{
"id": "003869-2026-4",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-171597",
"name": "The Royal Marsden NHS Foundation Trust"
}
]
},
{
"id": "003869-2026-5",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-10778",
"name": "Cambridge University Hospitals NHS Foundation Trust"
}
]
},
{
"id": "003869-2026-6",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-171598",
"name": "Oxford University Hospitals NHS FT"
}
]
},
{
"id": "003869-2026-7",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-171599",
"name": "University Hospitals Southampton"
}
]
},
{
"id": "003869-2026-8",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-72289",
"name": "University Hospitals Bristol and Weston NHS Foundation Trust"
}
]
},
{
"id": "003869-2026-9",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-171600",
"name": "UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST"
}
]
},
{
"id": "003869-2026-10",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-171601",
"name": "The Newcastle upon Tyne Hospitals NHS Foundation Trust"
}
]
},
{
"id": "003869-2026-11",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-171602",
"name": "The Christie NHS Foundation Trust"
}
]
},
{
"id": "003869-2026-12",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-171603",
"name": "THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST"
}
]
}
],
"bids": {
"statistics": [
{
"id": "1",
"measure": "bids",
"value": 4
},
{
"id": "2",
"measure": "bids",
"value": 4
},
{
"id": "3",
"measure": "bids",
"value": 4
},
{
"id": "4",
"measure": "bids",
"value": 4
},
{
"id": "5",
"measure": "bids",
"value": 1
},
{
"id": "6",
"measure": "bids",
"value": 2
},
{
"id": "7",
"measure": "bids",
"value": 2
},
{
"id": "8",
"measure": "bids",
"value": 2
},
{
"id": "9",
"measure": "bids",
"value": 3
},
{
"id": "10",
"measure": "bids",
"value": 2
},
{
"id": "11",
"measure": "bids",
"value": 2
},
{
"id": "12",
"measure": "bids",
"value": 2
}
]
},
"buyer": {
"id": "GB-FTS-130973",
"name": "NHS England"
},
"contracts": [
{
"awardID": "003869-2026-1",
"dateSigned": "2025-12-16T00:00:00Z",
"id": "003869-2026-1",
"status": "active",
"value": {
"amount": 11876000.0,
"currency": "GBP"
}
},
{
"awardID": "003869-2026-2",
"dateSigned": "2025-12-16T00:00:00Z",
"id": "003869-2026-2",
"status": "active",
"value": {
"amount": 11876000.0,
"currency": "GBP"
}
},
{
"awardID": "003869-2026-3",
"dateSigned": "2025-12-16T00:00:00Z",
"id": "003869-2026-3",
"status": "active",
"value": {
"amount": 11876000.0,
"currency": "GBP"
}
},
{
"awardID": "003869-2026-4",
"dateSigned": "2025-12-16T00:00:00Z",
"id": "003869-2026-4",
"status": "active",
"value": {
"amount": 11876000.0,
"currency": "GBP"
}
},
{
"awardID": "003869-2026-5",
"dateSigned": "2025-12-16T00:00:00Z",
"id": "003869-2026-5",
"status": "active",
"value": {
"amount": 11876000.0,
"currency": "GBP"
}
},
{
"awardID": "003869-2026-6",
"dateSigned": "2025-12-16T00:00:00Z",
"id": "003869-2026-6",
"status": "active",
"value": {
"amount": 11876000.0,
"currency": "GBP"
}
},
{
"awardID": "003869-2026-7",
"dateSigned": "2025-12-16T00:00:00Z",
"id": "003869-2026-7",
"status": "active",
"value": {
"amount": 11876000.0,
"currency": "GBP"
}
},
{
"awardID": "003869-2026-8",
"dateSigned": "2025-12-16T00:00:00Z",
"id": "003869-2026-8",
"status": "active",
"value": {
"amount": 11876000.0,
"currency": "GBP"
}
},
{
"awardID": "003869-2026-9",
"dateSigned": "2025-12-16T00:00:00Z",
"id": "003869-2026-9",
"status": "active",
"value": {
"amount": 11876000.0,
"currency": "GBP"
}
},
{
"awardID": "003869-2026-10",
"dateSigned": "2025-12-16T00:00:00Z",
"id": "003869-2026-10",
"status": "active",
"value": {
"amount": 11876000.0,
"currency": "GBP"
}
},
{
"awardID": "003869-2026-11",
"dateSigned": "2025-12-16T00:00:00Z",
"id": "003869-2026-11",
"status": "active",
"value": {
"amount": 11876000.0,
"currency": "GBP"
}
},
{
"awardID": "003869-2026-12",
"dateSigned": "2025-12-16T00:00:00Z",
"id": "003869-2026-12",
"status": "active",
"value": {
"amount": 11876000.0,
"currency": "GBP"
}
}
],
"date": "2026-01-16T12:42:41Z",
"description": "This is a Provider Selection Regime(PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award.\u003cbr/\u003e\u003cbr/\u003eThe standstill period begins on the day after the publication of this notice. Representations by providers must be made to the relevant authority by Wednesday 28th January 2026. Representations should be sent to jessica.gaucher-thompson@nhs.net. The award decision-makers are NHS England National Commissioning Group (NCG).\u003cbr/\u003e\u003cbr/\u003eThese contracts have not yet formally been awarded; this notice serves as an intention to award under the PSR.\u003cbr/\u003e\u003cbr/\u003eThe Key Criteria used for the award:\u003cbr/\u003eQuality \u0026 innovation: 50%\u003cbr/\u003eValue: 2%\u003cbr/\u003eIntegration, Collaboration \u0026 Service Sustainability: 21%\u003cbr/\u003eImproving Access, Reducing Health Inequalities and Facilitating Choice: 17%\u003cbr/\u003eSocial Value: 10%.\u003cbr/\u003e\u003cbr/\u003eThe rationale for selecting the provider(s) was based on them meeting all mandatory requirements and achieving the minimum quality threshold set out in the procurement documentation. This decision has been made as per NHS England governance processes, by the National Commissioning Group on 16th December 2025. No conflicts of Interest were identified amongst decision-makers.",
"id": "003869-2026",
"initiationType": "tender",
"language": "en",
"ocid": "ocds-h6vhtk-0595dd",
"parties": [
{
"address": {
"countryName": "United Kingdom",
"locality": "London",
"postalCode": "SE1 8UG",
"region": "UKJ1",
"streetAddress": "Wellington House, 133-135 Waterloo Rd"
},
"contactPoint": {
"email": "jessica.gaucher-thompson@nhs.net",
"name": "Jessica Gaucher-Thompson"
},
"details": {
"buyerProfile": "https://www.england.nhs.uk/",
"classifications": [
{
"description": "Body governed by public law",
"id": "BODY_PUBLIC",
"scheme": "TED_CA_TYPE"
},
{
"description": "Health",
"id": "07",
"scheme": "COFOG"
}
],
"url": "https://www.england.nhs.uk/"
},
"id": "GB-FTS-130973",
"identifier": {
"legalName": "NHS England"
},
"name": "NHS England",
"roles": [
"buyer"
]
},
{
"address": {
"countryName": "United Kingdom",
"locality": "London",
"postalCode": "NW1 2PG",
"region": "UKI"
},
"details": {
"scale": "large"
},
"id": "GB-FTS-171595",
"identifier": {
"legalName": "University College London Hospitals NHS Foundation Trust"
},
"name": "University College London Hospitals NHS Foundation Trust",
"roles": [
"supplier"
]
},
{
"address": {
"countryName": "United Kingdom",
"locality": "London",
"postalCode": "SE1 9RT",
"region": "UKI"
},
"details": {
"scale": "large"
},
"id": "GB-FTS-135891",
"identifier": {
"legalName": "Guy\u0027s and St Thomas\u0027 NHS Foundation Trust"
},
"name": "Guy\u0027s and St Thomas\u0027 NHS Foundation Trust",
"roles": [
"supplier"
]
},
{
"address": {
"countryName": "United Kingdom",
"locality": "London",
"postalCode": "E1 2ES",
"region": "UKI"
},
"details": {
"scale": "large"
},
"id": "GB-FTS-171596",
"identifier": {
"legalName": "Barts Health NHS Trust"
},
"name": "Barts Health NHS Trust",
"roles": [
"supplier"
]
},
{
"address": {
"countryName": "United Kingdom",
"locality": "London",
"postalCode": "SW3 6JJ",
"region": "UKI"
},
"details": {
"scale": "large"
},
"id": "GB-FTS-171597",
"identifier": {
"legalName": "The Royal Marsden NHS Foundation Trust"
},
"name": "The Royal Marsden NHS Foundation Trust",
"roles": [
"supplier"
]
},
{
"address": {
"countryName": "United Kingdom",
"locality": "Cambridge",
"postalCode": "CB2 0QQ",
"region": "UKH"
},
"details": {
"scale": "large"
},
"id": "GB-FTS-10778",
"identifier": {
"legalName": "Cambridge University Hospitals NHS Foundation Trust"
},
"name": "Cambridge University Hospitals NHS Foundation Trust",
"roles": [
"supplier"
]
},
{
"address": {
"countryName": "United Kingdom",
"locality": "Oxford",
"postalCode": "OX3 9DU",
"region": "UKJ"
},
"details": {
"scale": "large"
},
"id": "GB-FTS-171598",
"identifier": {
"legalName": "Oxford University Hospitals NHS FT"
},
"name": "Oxford University Hospitals NHS FT",
"roles": [
"supplier"
]
},
{
"address": {
"countryName": "United Kingdom",
"locality": "Southampton",
"postalCode": "SO16 6YD",
"region": "UKJ"
},
"details": {
"scale": "large"
},
"id": "GB-FTS-171599",
"identifier": {
"legalName": "University Hospitals Southampton"
},
"name": "University Hospitals Southampton",
"roles": [
"supplier"
]
},
{
"address": {
"countryName": "United Kingdom",
"locality": "Bristol",
"postalCode": "BS1 3NU",
"region": "UKK"
},
"details": {
"scale": "large"
},
"id": "GB-FTS-72289",
"identifier": {
"legalName": "University Hospitals Bristol and Weston NHS Foundation Trust"
},
"name": "University Hospitals Bristol and Weston NHS Foundation Trust",
"roles": [
"supplier"
]
},
{
"address": {
"countryName": "United Kingdom",
"locality": "Leicester",
"postalCode": "LE1 5WW",
"region": "UKF"
},
"details": {
"scale": "large"
},
"id": "GB-FTS-171600",
"identifier": {
"legalName": "UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST"
},
"name": "UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST",
"roles": [
"supplier"
]
},
{
"address": {
"countryName": "United Kingdom",
"locality": "Newcastle upon Tyne",
"postalCode": "NE1 4LP",
"region": "UKC"
},
"details": {
"scale": "large"
},
"id": "GB-FTS-171601",
"identifier": {
"legalName": "The Newcastle upon Tyne Hospitals NHS Foundation Trust"
},
"name": "The Newcastle upon Tyne Hospitals NHS Foundation Trust",
"roles": [
"supplier"
]
},
{
"address": {
"countryName": "United Kingdom",
"locality": "Manchester",
"postalCode": "M204BX",
"region": "UKD"
},
"details": {
"scale": "large"
},
"id": "GB-FTS-171602",
"identifier": {
"legalName": "The Christie NHS Foundation Trust"
},
"name": "The Christie NHS Foundation Trust",
"roles": [
"supplier"
]
},
{
"address": {
"countryName": "United Kingdom",
"locality": "Wirral",
"postalCode": "CH634JY",
"region": "UKD"
},
"details": {
"scale": "large"
},
"id": "GB-FTS-171603",
"identifier": {
"legalName": "THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST"
},
"name": "THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST",
"roles": [
"supplier"
]
},
{
"address": {
"countryName": "United Kingdom",
"locality": "Derby",
"postalCode": "DE1 3QT",
"streetAddress": "Cardinal Square, 10 Nottingham Road"
},
"details": {
"url": "https://www.ardengemcsu.nhs.uk/"
},
"id": "GB-FTS-141301",
"identifier": {
"legalName": "NHS Arden and Greater East Midlands Commissioning Support Unit"
},
"name": "NHS Arden and Greater East Midlands Commissioning Support Unit",
"roles": [
"reviewBody"
]
}
],
"tag": [
"award",
"contract"
],
"tender": {
"classification": {
"description": "Health services",
"id": "85100000",
"scheme": "CPV"
},
"coveredBy": [
"GPA"
],
"description": "NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults). \u003cbr/\u003e\u003cbr/\u003eLifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy\u003cbr/\u003eUnit (ITU).\u003cbr/\u003e\u003cbr/\u003eLifileucel is being assessed via NICE\u2019s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752\u003cbr/\u003e\u003cbr/\u003eThe treatment is complex to administer, requiring surgical expertise for tumour\u003cbr/\u003eresection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.\u003cbr/\u003e\u003cbr/\u003eThe key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:\u003cbr/\u003eLot 1: London\u003cbr/\u003eLot 2: East of England\u003cbr/\u003eLot 3: South East\u003cbr/\u003eLot 4: South West\u003cbr/\u003eLot 5: Midlands\u003cbr/\u003eLot 6: North East and Yorkshire\u003cbr/\u003eLot 7: North West\u003cbr/\u003e\u003cbr/\u003eThis process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.\u003cbr/\u003e\u003cbr/\u003eAs a result of this procurement exercise the commissioner intends to award 12 separate contracts across the 7 Lots.\u003cbr/\u003e\u003cbr/\u003eThe service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).",
"id": "ocds-h6vhtk-0595dd",
"items": [
{
"additionalClassifications": [
{
"description": "Health services",
"id": "85100000",
"scheme": "CPV"
}
],
"deliveryAddresses": [
{
"region": "UKI"
}
],
"id": "1",
"relatedLot": "1"
},
{
"additionalClassifications": [
{
"description": "Health services",
"id": "85100000",
"scheme": "CPV"
}
],
"deliveryAddresses": [
{
"region": "UKH"
}
],
"id": "2",
"relatedLot": "2"
},
{
"additionalClassifications": [
{
"description": "Health services",
"id": "85100000",
"scheme": "CPV"
}
],
"deliveryAddresses": [
{
"region": "UKJ"
}
],
"id": "3",
"relatedLot": "3"
},
{
"additionalClassifications": [
{
"description": "Health services",
"id": "85100000",
"scheme": "CPV"
}
],
"deliveryAddresses": [
{
"region": "UKK"
}
],
"id": "4",
"relatedLot": "4"
},
{
"additionalClassifications": [
{
"description": "Health services",
"id": "85100000",
"scheme": "CPV"
}
],
"deliveryAddresses": [
{
"region": "UKF"
},
{
"region": "UKG"
}
],
"id": "5",
"relatedLot": "5"
},
{
"additionalClassifications": [
{
"description": "Health services",
"id": "85100000",
"scheme": "CPV"
}
],
"deliveryAddresses": [
{
"region": "UKC"
},
{
"region": "UKE"
}
],
"id": "6",
"relatedLot": "6"
},
{
"additionalClassifications": [
{
"description": "Health services",
"id": "85100000",
"scheme": "CPV"
}
],
"deliveryAddresses": [
{
"region": "UKD"
}
],
"id": "7",
"relatedLot": "7"
}
],
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"lots": [
{
"awardCriteria": {
"criteria": [
{
"description": "50",
"name": "Quality \u0026 innovation",
"type": "quality"
},
{
"description": "2",
"name": "Value",
"type": "quality"
},
{
"description": "21",
"name": "Integration, Collaboration \u0026 Service Sustainability",
"type": "quality"
},
{
"description": "17",
"name": "Improving Access, Reducing Health Inequalities and Facilitating Choice",
"type": "quality"
},
{
"description": "10",
"name": "Social Value",
"type": "quality"
},
{
"description": "0",
"name": "Not Applicable",
"type": "cost"
}
]
},
"description": "NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).\u003cbr/\u003e\u003cbr/\u003eLifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy\u003cbr/\u003eUnit (ITU).\u003cbr/\u003e\u003cbr/\u003eLifileucel is being assessed via NICE\u2019s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752\u003cbr/\u003e\u003cbr/\u003eThe treatment is complex to administer, requiring surgical expertise for tumour\u003cbr/\u003eresection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.\u003cbr/\u003e\u003cbr/\u003eThe key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:\u003cbr/\u003eLot 1: London\u003cbr/\u003eLot 2: East of England\u003cbr/\u003eLot 3: South East\u003cbr/\u003eLot 4: South West\u003cbr/\u003eLot 5: Midlands\u003cbr/\u003eLot 6: North East and Yorkshire\u003cbr/\u003eLot 7: North West\u003cbr/\u003e\u003cbr/\u003eThis process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.\u003cbr/\u003e\u003cbr/\u003eAs a result of this procurement exercise, the Commissioner intends to award four separate contracts under Lot 1 - London. \u003cbr/\u003e\u003cbr/\u003eThe approximate lifetime value of each contract is \u00a311,876,000, subject to the number of patients treated.\u003cbr/\u003e\u003cbr/\u003eThe service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).",
"hasOptions": true,
"id": "1",
"options": {
"description": "Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s)."
},
"status": "cancelled",
"title": "Lot 1 - London"
},
{
"awardCriteria": {
"criteria": [
{
"description": "50",
"name": "Quality \u0026 innovation",
"type": "quality"
},
{
"description": "2",
"name": "Value",
"type": "quality"
},
{
"description": "21",
"name": "Integration, Collaboration \u0026 Service Sustainability",
"type": "quality"
},
{
"description": "17",
"name": "Improving Access, Reducing Health Inequalities and Facilitating Choice",
"type": "quality"
},
{
"description": "10",
"name": "Social Value",
"type": "quality"
},
{
"description": "0",
"name": "Not Applicable",
"type": "cost"
}
]
},
"description": "NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).\u003cbr/\u003e\u003cbr/\u003eLifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy\u003cbr/\u003eUnit (ITU).\u003cbr/\u003e\u003cbr/\u003eLifileucel is being assessed via NICE\u2019s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752\u003cbr/\u003e\u003cbr/\u003eThe treatment is complex to administer, requiring surgical expertise for tumour\u003cbr/\u003eresection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.\u003cbr/\u003e\u003cbr/\u003eThe key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:\u003cbr/\u003eLot 1: London\u003cbr/\u003eLot 2: East of England\u003cbr/\u003eLot 3: South East\u003cbr/\u003eLot 4: South West\u003cbr/\u003eLot 5: Midlands\u003cbr/\u003eLot 6: North East and Yorkshire\u003cbr/\u003eLot 7: North West\u003cbr/\u003e\u003cbr/\u003eThis process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.\u003cbr/\u003e\u003cbr/\u003eAs a result of this procurement exercise, the Commissioner intends to award a contract under Lot 2 - East of England.\u003cbr/\u003e\u003cbr/\u003eThe approximate lifetime value of the contract is \u00a311,876,000, subject to the number of patients treated.\u003cbr/\u003e\u003cbr/\u003eThe service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).",
"hasOptions": true,
"id": "2",
"options": {
"description": "Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s)."
},
"status": "cancelled",
"title": "Lot 2 - East of England"
},
{
"awardCriteria": {
"criteria": [
{
"description": "50",
"name": "Quality \u0026 innovation",
"type": "quality"
},
{
"description": "2",
"name": "Value",
"type": "quality"
},
{
"description": "21",
"name": "Integration, Collaboration \u0026 Service Sustainability",
"type": "quality"
},
{
"description": "17",
"name": "Improving Access, Reducing Health Inequalities and Facilitating Choice",
"type": "quality"
},
{
"description": "10",
"name": "Social Value",
"type": "quality"
},
{
"description": "0",
"name": "Not Applicable",
"type": "cost"
}
]
},
"description": "NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).\u003cbr/\u003e\u003cbr/\u003eLifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy\u003cbr/\u003eUnit (ITU).\u003cbr/\u003e\u003cbr/\u003eLifileucel is being assessed via NICE\u2019s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752\u003cbr/\u003e\u003cbr/\u003eThe treatment is complex to administer, requiring surgical expertise for tumour\u003cbr/\u003eresection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.\u003cbr/\u003e\u003cbr/\u003eThe key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:\u003cbr/\u003eLot 1: London\u003cbr/\u003eLot 2: East of England\u003cbr/\u003eLot 3: South East\u003cbr/\u003eLot 4: South West\u003cbr/\u003eLot 5: Midlands\u003cbr/\u003eLot 6: North East and Yorkshire\u003cbr/\u003eLot 7: North West\u003cbr/\u003e\u003cbr/\u003eThis process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.\u003cbr/\u003e\u003cbr/\u003eAs a result of this procurement exercise, the Commissioner intends to award two separate contracts under Lot 3 - South East.\u003cbr/\u003e\u003cbr/\u003eThe approximate lifetime value of each contract is \u00a311,876,000, subject to the number of patients treated.\u003cbr/\u003e\u003cbr/\u003eThe service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).",
"hasOptions": true,
"id": "3",
"options": {
"description": "Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s)."
},
"status": "cancelled",
"title": "Lot 3: South East"
},
{
"awardCriteria": {
"criteria": [
{
"description": "50",
"name": "Quality \u0026 innovation",
"type": "quality"
},
{
"description": "2",
"name": "Value",
"type": "quality"
},
{
"description": "21",
"name": "Integration, Collaboration \u0026 Service Sustainability",
"type": "quality"
},
{
"description": "17",
"name": "Improving Access, Reducing Health Inequalities and Facilitating Choice",
"type": "quality"
},
{
"description": "10",
"name": "Social Value",
"type": "quality"
},
{
"description": "0",
"name": "Not Applicable",
"type": "cost"
}
]
},
"description": "NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).\u003cbr/\u003e\u003cbr/\u003eLifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy\u003cbr/\u003eUnit (ITU).\u003cbr/\u003e\u003cbr/\u003eLifileucel is being assessed via NICE\u2019s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752\u003cbr/\u003e\u003cbr/\u003eThe treatment is complex to administer, requiring surgical expertise for tumour\u003cbr/\u003eresection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.\u003cbr/\u003e\u003cbr/\u003eThe key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:\u003cbr/\u003eLot 1: London\u003cbr/\u003eLot 2: East of England\u003cbr/\u003eLot 3: South East\u003cbr/\u003eLot 4: South West\u003cbr/\u003eLot 5: Midlands\u003cbr/\u003eLot 6: North East and Yorkshire\u003cbr/\u003eLot 7: North West\u003cbr/\u003e\u003cbr/\u003eThis process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.\u003cbr/\u003e\u003cbr/\u003eAs a result of this procurement exercise, the Commissioner intends to award a contract under Lot 4 - South West.\u003cbr/\u003e\u003cbr/\u003eThe approximate lifetime value of the contract is \u00a311,876,000, subject to the number of patients treated.\u003cbr/\u003e\u003cbr/\u003eThe service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).",
"hasOptions": true,
"id": "4",
"options": {
"description": "Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s)."
},
"status": "cancelled",
"title": "Lot 4: South West"
},
{
"awardCriteria": {
"criteria": [
{
"description": "50",
"name": "Quality \u0026 innovation",
"type": "quality"
},
{
"description": "2",
"name": "Value",
"type": "quality"
},
{
"description": "21",
"name": "Integration, Collaboration \u0026 Service Sustainability",
"type": "quality"
},
{
"description": "17",
"name": "Improving Access, Reducing Health Inequalities and Facilitating Choice",
"type": "quality"
},
{
"description": "10",
"name": "Social Value",
"type": "quality"
},
{
"description": "0",
"name": "Not Applicable",
"type": "cost"
}
]
},
"description": "NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).\u003cbr/\u003e\u003cbr/\u003eLifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy\u003cbr/\u003eUnit (ITU).\u003cbr/\u003e\u003cbr/\u003eLifileucel is being assessed via NICE\u2019s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752\u003cbr/\u003e\u003cbr/\u003eThe treatment is complex to administer, requiring surgical expertise for tumour\u003cbr/\u003eresection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.\u003cbr/\u003e\u003cbr/\u003eThe key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:\u003cbr/\u003eLot 1: London\u003cbr/\u003eLot 2: East of England\u003cbr/\u003eLot 3: South East\u003cbr/\u003eLot 4: South West\u003cbr/\u003eLot 5: Midlands\u003cbr/\u003eLot 6: North East and Yorkshire\u003cbr/\u003eLot 7: North West\u003cbr/\u003e\u003cbr/\u003eThis process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.\u003cbr/\u003e\u003cbr/\u003eAs a result of this procurement exercise, the Commissioner intends to award a contract under Lot 5 - Midlands.\u003cbr/\u003e\u003cbr/\u003eThe approximate lifetime value of the contract is \u00a311,876,000, subject to the number of patients treated.\u003cbr/\u003e\u003cbr/\u003eThe service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).",
"hasOptions": true,
"id": "5",
"options": {
"description": "Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s)."
},
"status": "cancelled",
"title": "Lot 5: Midlands"
},
{
"awardCriteria": {
"criteria": [
{
"description": "50",
"name": "Quality \u0026 innovation",
"type": "quality"
},
{
"description": "2",
"name": "Value",
"type": "quality"
},
{
"description": "21",
"name": "Integration, Collaboration \u0026 Service Sustainability",
"type": "quality"
},
{
"description": "17",
"name": "Improving Access, Reducing Health Inequalities and Facilitating Choice",
"type": "quality"
},
{
"description": "10",
"name": "Social Value",
"type": "quality"
},
{
"description": "0",
"name": "Not Applicable",
"type": "cost"
}
]
},
"description": "NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).\u003cbr/\u003e\u003cbr/\u003eLifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy\u003cbr/\u003eUnit (ITU).\u003cbr/\u003e\u003cbr/\u003eLifileucel is being assessed via NICE\u2019s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752\u003cbr/\u003e\u003cbr/\u003eThe treatment is complex to administer, requiring surgical expertise for tumour\u003cbr/\u003eresection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.\u003cbr/\u003e\u003cbr/\u003eThe key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:\u003cbr/\u003eLot 1: London\u003cbr/\u003eLot 2: East of England\u003cbr/\u003eLot 3: South East\u003cbr/\u003eLot 4: South West\u003cbr/\u003eLot 5: Midlands\u003cbr/\u003eLot 6: North East and Yorkshire\u003cbr/\u003eLot 7: North West\u003cbr/\u003e\u003cbr/\u003eThis process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.\u003cbr/\u003e\u003cbr/\u003eAs a result of this procurement exercise, the Commissioner intends to award a contract under Lot 6 - North East and Yorkshire.\u003cbr/\u003e\u003cbr/\u003eThe approximate lifetime value of the contract is \u00a311,876,000, subject to the number of patients treated.\u003cbr/\u003e\u003cbr/\u003eThe service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).",
"hasOptions": true,
"id": "6",
"options": {
"description": "Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s)."
},
"status": "cancelled",
"title": "Lot 6: North East \u0026 Yorkshire"
},
{
"awardCriteria": {
"criteria": [
{
"description": "50",
"name": "Quality \u0026 innovation",
"type": "quality"
},
{
"description": "2",
"name": "Value",
"type": "quality"
},
{
"description": "21",
"name": "Integration, Collaboration \u0026 Service Sustainability",
"type": "quality"
},
{
"description": "17",
"name": "Improving Access, Reducing Health Inequalities and Facilitating Choice",
"type": "quality"
},
{
"description": "10",
"name": "Social Value",
"type": "quality"
},
{
"description": "0",
"name": "Not Applicable",
"type": "cost"
}
]
},
"description": "NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).\u003cbr/\u003e\u003cbr/\u003eLifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy\u003cbr/\u003eUnit (ITU).\u003cbr/\u003e\u003cbr/\u003eLifileucel is being assessed via NICE\u2019s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752\u003cbr/\u003e\u003cbr/\u003eThe treatment is complex to administer, requiring surgical expertise for tumour\u003cbr/\u003eresection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.\u003cbr/\u003e\u003cbr/\u003eThe key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:\u003cbr/\u003eLot 1: London\u003cbr/\u003eLot 2: East of England\u003cbr/\u003eLot 3: South East\u003cbr/\u003eLot 4: South West\u003cbr/\u003eLot 5: Midlands\u003cbr/\u003eLot 6: North East and Yorkshire\u003cbr/\u003eLot 7: North West\u003cbr/\u003e\u003cbr/\u003eThis process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.\u003cbr/\u003e\u003cbr/\u003eAs a result of this procurement exercise, the Commissioner intends to award two separate contracts under Lot 7 - North West.\u003cbr/\u003e\u003cbr/\u003eThe approximate lifetime value of each contract is \u00a311,876,000, subject to the number of patients treated.\u003cbr/\u003e\u003cbr/\u003eThe service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).",
"hasOptions": true,
"id": "7",
"options": {
"description": "Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s)."
},
"status": "cancelled",
"title": "Lot 7: North West"
}
],
"mainProcurementCategory": "services",
"procurementMethod": "open",
"procurementMethodDetails": "Open procedure",
"status": "complete",
"title": "Tumour Infiltrating Lymphocyte(TIL) Therapy Hubs for Melanoma(Adults)"
}
}